Article Text

Download PDFPDF

Highlights from this issue
Free
  1. Jackie A Cassell, Editor in Chief

Statistics from Altmetric.com

Once upon a time, it all seemed so simple. Early trials of chlamydia screening looked promising in reducing the incidence of pelvic inflammatory disease, so attention quickly turned to evaluating means of delivery, and it was widely assumed that prevalence would rapidly fall. As the optimism of a new millennium faded, chlamydia prevalence was shown in a range of studies to remain stubbornly resistant to control activities or to decline regardless of testing patterns. A number of population based studies suggest that pelvic inflammatory disease (PID) is also in decline in many settings, for reasons which remain unclear. So what is the impact of chlamydia screening or other control activities? Are we selecting for less symptomatic strains (and if so, are they less damaging …

View Full Text

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.